YHLO Closed a Strategic Investment Led by Sinopharm Capital

According to Lieyunwang, Shenzhen YHLO Biotech Co., Ltd. (YHLO) announced that it had got the strategic investment led by Sinopharm Capital, followed by Shenzhen Capital Group, Lilly Asia Ventures, SAIF Partners, and Bioventure.

YHLO is a leading company of immunoassay solutions in China. Founded in 2002 and headquartered in Shenzhen, China, YHLO is committed to developing, manufacturing and distributing in-vitro diagnostic instruments and reagents.

YHLO has strategic cooperation with famous universities, research institutes and high-tech enterprises from the USA, Germany, Italy, etc. The company is dedicated to meeting global clinical demands and developing instruments and reagents with our own intellectual properties. 

Based on the technology platforms of CLIA, ELISA, LIA, and immunofluorescence, YHLO is specialized in the diagnosis of autoimmunity, reproductive health, diabetes, infectious diseases, etc. Most YHLO products are CFDA certified and CE marked and have entered more than 60 countries across Europe, Australia, Latin America, Africa, and Asia.

Founded by Sinopharm Group in 2012, Sinopharm Capital is an equity investment institution focusing on medical and health. The management team is composed of professional investors who have a deep understanding of the development and capital operation of the medical and health industry. The company integrates internal and external resources and capital of Sinopharm Group. The fund management scale of Sinopharm Capital is more than 6 billion yuan.

LAV is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. It focuses on biopharmaceuticals, human therapeutics, medical devices, and diagnostics. The company’s vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health.